| DexCom™, Inc., headquartered in San Diego, California, is a company focused on pioneering technologies for the continuous monitoring of glucose in people with diabetes. DexCom has developed a short term continuous glucose monitoring system, the Seven™ System, which includes the Seven Sensor, the Seven Transmitter, and the Seven Receiver.
The tiny probe-like Sensor is inserted by the user under the skin, and is held in place by an adhesive. Once inserted, the Sensor begins continuously monitoring glucose. The Transmitter sends the glucose signal from the Sensor and wirelessly transmits the data to the hand-held Receiver. The Receiver processes the glucose signal and with the push of a button, displays the user’s current glucose value, as well as 1-hr, 3-hr, and 9-hr trends. The Receiver also sounds an alert when a high or low glucose excursion is detected.
Clinical research using DexCom’s continuous glucose monitoring system has shown1,2,3:
- The DexCom continuous glucose monitoring system is safe and accurate
- Users were able to reduce time spent hyperglycemic and hypoglycemic, while simultaneously increasing time spent in target glucose range
- Users demonstrated statistically significant improvements in glycemic profiles with no guidance or therapeutic adjustments from physicians
- Users with both good and poor control show improvements in glycemic control
- Access to night-time glucose values and
alerts/alarms give users the opportunity to treat glycemic excursions that they may never be aware of otherwise.
- Garg S et al. Improvement in Glycemic Excursions With a Transcutaneous, Real-Time Continuous Glucose Sensor, Diabetes Care, 29:44-50, January 2006
- Garg S and Jovanovic L. Relationship of Fasting and the Hourly Blood Glucose Levels to HbA1c Values, Diabetes Care, 29:2644-2694, December 2006.
- Timothy Bailey et al. Reduction in Hemoglobin A1c with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study, Diabetes Technology & Therapeutics, 9:203-210, June 2007.
|
